Dr Ganeko Bernardo-Seisdedos is a Research Fellow at the University of Deusto, where he leads a new research line focused on the biophysical and structural characterisation of the ALS-linked proteins CHCHD10 and TDP-43, aiming to develop theragnostic chaperones against pathological aggregation. His work combines NMR spectroscopy, molecular modeling, mutational analysis, and cellular assays to understand how protein instability drives neurodegeneration. Alongside this effort, he is involved in projects applying ³¹P-NMR phosphoromics to analyse metabolic and energetic dysregulation in patient-derived biofluids, with the goal of identifying molecular markers for precision medicine in ALS and related disorders. He earned his PhD in Molecular Biology and Biomedicine at UPV/EHU (2015), where he resolved the calcium-dependent gating mechanism of Kv7.2 potassium channels at atomic resolution. Before joining Deusto, he worked at ATLAS Molecular Pharma, developing an NMR-based platform for pharmacological chaperone discovery and contributing to patents for porphyria and prion disease therapeutics.